Anti-neutrophil cytoplasmic antibodies (ANCA) specific for one or several antigens: Useful markers for subtypes of ulcerative colitis and associated primary sclerosing cholangitis

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 3, 2012, Pages 503-509

  Dobric, Senka ^a   Popovic, Dragan ^a,b   Nikolic, Milos ^a,b   Andrejevic, Sladjana ^a   Spuran, Milan ^a,b   Bonaci Nikolic, Branka ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

anti neutrophil cytoplasmic antibodies (ANCA); anti nuclear antibodies; anti smooth muscle antibodies; bactericidal permeability increasing ANCA; primary sclerosing cholangitis; ulcerative colitis

Indexed keywords

BACTERICIDAL PERMEABILITY INCREASING PROTEIN; CATHEPSIN G; ELASTASE; LACTOFERRIN; LYSOZYME; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; SMOOTH MUSCLE ANTIBODY;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; CONCENTRATION (PARAMETERS); DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SEROLOGY; ULCERATIVE COLITIS;

ADULT; AGED; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODY SPECIFICITY; ANTIGENS; BIOLOGICAL MARKERS; CHOLANGITIS, SCLEROSING; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGAN SPECIFICITY; TIME FACTORS;

BACTERIA (MICROORGANISMS);

EID: 84860455313     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm.2011.797     Document Type: Article

References (39)

1. Lakatos PL, Fischer S, Lakatos L, Gal I, Papp J. Current concept on the pathogenesis of infl ammatory bowel disease-crosstalk between genetic and microbial factors: pathogenic bacteria and altered bacterial sensing or changes in mucosal integrity take " toll " ? World J Gastroenterol 2006 12 1829-41.
2. Gazouli M, Mantzaris G, Kotsinas A, Zacharatos P, Papalambros E, Archimandritis A, et al. Association between polymorphisms in the Toll-like receptor 4, CD14, and CARD15/NOD2 and infl ammatory bowel disease in the Greek population. World J Gastroenterol 2005;11:681-5. (Pubitemid 40220757)
3. Bossuyt X. Serologic markers in infl ammatory bowel disease. Clin Chem 2006;52:171-81. (Pubitemid 43185477)
4. Roozendaal C, Pog á ny K, Horst G, Jagt TG, Kleibeuker JH, Nelis GF, et al. Does analysis of the antigenic specifi cities of anti-neutrophil cytoplasmic antibodies contribute to their clinical signifi - cance in the infl ammatory bowel diseases ? Scand J Gastroenterol 1999 34 1123-31.
5. Castro-Santos P, Suarez A, Mozo L, Gutierrez C. Association of IL-10 and TNF alpha genotypes with ANCA appearance in ulcerative colitis. Clin Immunol 2007;122:108-14. (Pubitemid 46026697)
6. Sobajima J, Ozaki S, Osakada F, Uesugi H, Shirakawa H, Yoshida M, et al. Novel autoantigens of perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA) in ulcerative colitis: non-histone chromosomal proteins, HMG1 and HMG2. Clin Exp Immunol 1997;107:135-40. (Pubitemid 27019822)
7. Terjung B, Herzog V, Worman HJ, Gestmann I, Bauer C, Sauerbruch T, et al. Atypical antineutrophil cytoplasmic antibodies with perinuclear fl uorescence in chronic infl ammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins. Hepatology 1998;28:332-40. (Pubitemid 28363656)
8. Schmitt WH, van der Woude FJ. Clinical applications of antineutrophil cytoplasmic antibody testing. Curr Opin Rheumatol 2004;16:9-17. (Pubitemid 38041393)
9. Roozendaal C, de Jong MA, van den Berg AP, van Wijk RT, Limburg PC, Kallenberg CG. Clinical signifi cance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases. J Hepatol 2000;32:734-41. (Pubitemid 30262732)
10. Schultz H, Schinke S, Weiss J, Cerundolo V, Gross WL, Gadola S. BPI-ANCA in transporter associated with antigen presentation (TAP) defi ciency: possible role in susceptibility to Gram-negative bacterial infections. Clin Exp Immunol 2003;133:252-9. (Pubitemid 36918600)
11. Carlsson M, Eriksson L, Pressler T, Kornf ä lt R, Mared L, Meyer P, et al. Autoantibody response to BPI predict disease severity and outcome in cystic fi brosis. J Cyst Fibros 2007;6:228-33.
12. Schultz H. From infection to autoimmunity: a new model for induction of ANCA against the bactericidal/permeability increasing protein (BPI). Autoimmun Rev 2007;6:223-7. (Pubitemid 46274546)
13. Terjung B, Spengler U. Atypical p-ANCA in PSC and AIH: a hint toward a " leaky gut " ? Clinic Rev Allerg Immunol 2009 36 40-51.
14. Hanauer SB. Infl ammatory bowel disease. N Engl J Med 1996;334:841-88.
15. D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, et al. A review of activity indices and effi cacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763-86.
16. Yoshida EM. The Crohn's Disease Activity Index, its derivatives and the Infl ammatory Bowel Disease Questionnaire: a review of instruments to assess Crohn's disease. Can J Gastroenterol 1999;13:65-73. (Pubitemid 29158482)
17. Radice A, Vecchi M, Bianchi MB, Sinico RA. Contribution of immunofl orescence to the identifi cation and characterization of anti-neutrophil cytoplasmic autoantibodies. The role of different fi xatives. Clin Exp Rheum 2000;18:707-12.
18. Reumaux D, Colombel JF, Masy E, Duclos B, Heresbach D, Belaüche J. Anti-neutrophil cytoplasmic auto-antibodies (ANCA) in ulcerative colitis (UC): no relationship with disease activity. Infl amm Bowel Dis 2000;6:270-4.
19. Savige J, Nassis L, Cooper T, Paspaliaris B, Martinello P, MacGregor D. Antineutrophil cytoplasmic antibody (ANCA)- associated systemic vasculitis after immunisation with bacterial proteins. Clin Exp Rheumatol 2002;20:783-90.
20. Hurtado PR, Jeffs L, Nitschke J, Patel M, Sarvestani G, Cassidy J, et al. CpG oligodeoxynucleotide stimulates production of antineutrophil cytoplasmic antibodies in ANCA associated vasculitis. BMC Immunol 2008;9:34.
21. Cohavy O, Bruckner D, Gordon LK, Misra R, Wei B, Eggena ME, et al. Colonic bacteria express an ulcerative colitis pANCArelated protein epitope. Infect Immun 2000;68:1542-8. (Pubitemid 30108556)
22. Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis. Am J Gastroenterol 1995;90:740-7.
23. Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc 1996;71:431-6. (Pubitemid 26144146)
24. Yang JJ, Tuttle RH, Hogan SL, Taylor JG, Phillips BD, Falk RJ. Target antigens for anti-neutrophil cytoplasmic autoantibodies (ANCA) are on the surface of primed and apoptotic but not unstimulated neutrophils. Clin Exp Immunol 2000;121:165-72. (Pubitemid 30436031)
25. Stoffel MP, Csernok E, Herzberg C, Johnson T, Carroll SF, Gross WL. Anti-neutrophil cytoplasmic antibodies (ANCA) directed against bactericidal/permeability increasing protein (BPI): a new seromarker for infl ammatory bowel disease and associated disorders. Clin Exp Immunol 1996;104:54-9. (Pubitemid 26103413)
26. Levy O. A neutrophil-derived anti-infective molecule: bactericidal/permeability-increasing protein. Antimicrob Agents Chemother 2000;44:2925-31.
27. Bank U, Ansorge S. More than destructive: neutrophil-derived serine proteases in cytokine bioactivity control. J Leukoc Biol 2001;69:197-206. (Pubitemid 32163431)
28. Csernok E, Holle JU, Gross WL. Proteinase 3, protease-activated receptor-2 and interleukin-32: linking innate and autoimmunity in Wegener's granulomatosis. Clin Exp Rheumatol 2008;26:S112-7.
29. Preston GA, Zarella CS, Pendergraft WF 3rd, Rudolph EH, Yang JJ, Sekura SB, et al. Novel effects of neutrophil-derived proteinase 3 and elastase on the vascular endothelium involve in vivo cleavage of NF- B and proapoptotic changes in JNK, ERK, and p38 MAPK signaling pathways. J Am Soc Nephrol 2002;13:2840-9. (Pubitemid 35386903)
30. Sobajima J, Ozaki S, Okazaki T, Osakada F, Sumita S, Mori K, et al. Anti-neutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis: anti-cathepsin G and a novel antibody correlate with a refractory type. Clin Exp Immunol 1996;105:120-4. (Pubitemid 26231834)
31. Xu J, Yang CH, Chen XY, Li XH, Dai M, Xiao SD. A subset of ulcerative colitis with positive proteinase-3 antineutrophil cytoplasmic antibody. World J Gastroenterol 2008;14:7012-5.
32. Hov J, Boberg K, Karlsen T. Autoantibodies in primary sclerosing cholangitis. World J Gastroenterol 2008;14:3781-91.
33. Lombardi G, Annese V, Piepoli A, Bovio P, Latiano A, Napolitano G, et al. Antineutrophil cytoplasmic antibodies in infl ammatory bowel disease: clinical role and review of the literature. Dis Colon Rectum 2000;43:999-1007. (Pubitemid 30464074)
34. Pokorny CS, Norton ID, McCaughan GW, Selby WS. Antineutrophil cytoplasmic antibody: a prognostic indicator in primary sclerosing cholangitis. J Gastroenterol Hepatol 1994;9:40-4. (Pubitemid 24041947)
35. Gonsky R, Deem RL, Landers CJ, Derkowski CA, Berel D, McGovern DP, et al. Distinct IFNG methylation in a subset of ulcerative colitis patients based on reactivity to microbial antigens. Infl amm Bowel Dis 2011;17:171-8.
36. Papayannopoulos V, Zychlinsky A. NETs: a new strategy for using old weapons. Trends Immunol 2009;30:513-21.
37. Teegen B, Niemann S, Probst C, Schlumberger W, St ö cker W, Komorowski L. DNA-bound lactoferrin is the major target for antineutrophil perinuclear cytoplasmic antibodies in ulcerative colitis. Ann N Y Acad Sci 2009;1173:161-5.
38. Neeli I, Khan SN, Radic M. Histone deimination as a response to infl ammatory stimuli in neutrophils. J Immunol 2008;180:1895-902.
39. Jürgens M, Laubender RP, Hartl F, Weidinger M, Seiderer J, Wagner J, et al. Disease activity, ANCA, and IL23R genotype status determine early response to infl iximab in patients with ulcerative colitis. Am J Gastroenterol 2010;105:1811-9.